Ftse Mib
34.307,17
-0,20%
DAX
18.523,52
-0,41%
S&P 500
5.631,22
0,28%
NASDAQ
18.472,57
0,40%
Bitcoin
63.527,78
-2,04%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ AbCellera Biologics Inc (ABCL) AbCellera Biologics Inc (ABCL) Notizie

ABCL

AbCellera Biologics (ABCL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ABCL
DataOraFonteTitoloSimboloCompagnia
04/02/202200:55Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:ABCLAbCellera Biologics Inc
27/01/202222:05Business WireAbCellera to Report Full Year 2021 Financial Results on February 24, 2022NASDAQ:ABCLAbCellera Biologics Inc
21/12/202113:47TipRanksBloom Burton Initiates a Buy Rating on AbCellera Biologics (ABCL)NASDAQ:ABCLAbCellera Biologics Inc
10/12/202123:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ABCLAbCellera Biologics Inc
07/12/202122:05Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:ABCLAbCellera Biologics Inc
07/12/202122:00Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ABCLAbCellera Biologics Inc
07/12/202115:00Business WireAbCellera Announces Changes to Its Board of DirectorsNASDAQ:ABCLAbCellera Biologics Inc
03/12/202123:48Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:ABCLAbCellera Biologics Inc
03/12/202122:05Business WireAbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12NASDAQ:ABCLAbCellera Biologics Inc
02/12/202115:00Business WireAbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial OfficerNASDAQ:ABCLAbCellera Biologics Inc
10/11/202122:18Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ABCLAbCellera Biologics Inc
09/11/202122:05Business WireAbCellera Reports Q3 2021 Business ResultsNASDAQ:ABCLAbCellera Biologics Inc
04/11/202121:05Business WireAbCellera Announces Virtual Presentations at Investor Conferences in NovemberNASDAQ:ABCLAbCellera Biologics Inc
02/11/202121:04Business WireLilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19NASDAQ:ABCLAbCellera Biologics Inc
14/10/202122:05Business WireAbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021NASDAQ:ABCLAbCellera Biologics Inc
23/09/202100:00Business WireAbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody TherapiesNASDAQ:ABCLAbCellera Biologics Inc
21/09/202119:55Business WireLilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19NASDAQ:ABCLAbCellera Biologics Inc
17/09/202112:37TipRanksFDA Extends EUA for AbCellera’s Bamlanivimab; Shares Rally 19.8%NASDAQ:ABCLAbCellera Biologics Inc
16/09/202122:15Business WireEmergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19NASDAQ:ABCLAbCellera Biologics Inc
16/09/202108:39TipRanksAbCellera Collaborates with Moderna; Shares Rise 7.1%NASDAQ:ABCLAbCellera Biologics Inc
15/09/202115:00Business WireAbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA MedicinesNASDAQ:ABCLAbCellera Biologics Inc
13/09/202115:00Business WireAbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value TargetsNASDAQ:ABCLAbCellera Biologics Inc
10/09/202122:17Business WireAbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery ConferenceNASDAQ:ABCLAbCellera Biologics Inc
12/08/202122:05Business WireAbCellera Reports Q2 2021 Business ResultsNASDAQ:ABCLAbCellera Biologics Inc
04/08/202113:00Business WireEQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative MedicinesNASDAQ:ABCLAbCellera Biologics Inc
03/08/202112:00Business WireTachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of CancerNASDAQ:ABCLAbCellera Biologics Inc
22/07/202122:05Business WireAbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021NASDAQ:ABCLAbCellera Biologics Inc
13/07/202115:00Business WireAbCellera Appoints Neil Berkley as Chief Business OfficerNASDAQ:ABCLAbCellera Biologics Inc
22/06/202115:00Business WireAbCellera Continues Expansion & Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility f...NASDAQ:ABCLAbCellera Biologics Inc
10/06/202123:18Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:ABCLAbCellera Biologics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ABCL

La tua Cronologia

LSE
0LX9
Platforma Mediowa Point
LSE
71HN
Mercantile 4q%
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network